Metformin - Diabetes - Patient guide

Metformin is the most widely prescribed oral diabetes medication in the world and the standard first-line pharmacological treatment for type 2 diabetes according to major clinical guidelines. It belongs to the biguanide class and works primarily by reducing hepatic glucose production, which is the main driver of elevated fasting blood glucose in type 2 diabetes. Secondary mechanisms include modest improvements in peripheral insulin sensitivity and slowing intestinal glucose absorption. Unlike insulin and sulfonylureas, metformin does not stimulate insulin release. This means it does not cause hypoglycemia when used as monotherapy, a significant safety advantage that makes it particularly suitable for initial treatment and for long-term therapy in patients who need to avoid blood sugar lows. Weight gain is not typically associated with metformin use, and some patients experience modest weight reduction. Metformin has been in clinical use since the 1950s in Europe and was approved in the United States in the 1990s. Decades of clinical trial data support its effectiveness in lowering hemoglobin A1C, typically by 1 to 1.5 percentage points, and landmark trials including the United Kingdom Prospective Diabetes Study demonstrated reductions in diabetes-related complications in patients treated with metformin compared to less intensive management. Beyond glucose control, metformin has shown cardiovascular-protective signals in clinical trial data, making it relevant for the common population of patients with type 2 diabetes who are also at elevated cardiovascular risk. This additional benefit profile supports its continued first-line status in guidelines that incorporate comprehensive risk reduction goals. Gastrointestinal side effects represent the most common tolerability challenge with metformin. Nausea, diarrhea, abdominal discomfort, and flatulence affect a meaningful proportion of patients, particularly during initiation. These effects are dose-related and manageable with gradual dose titration and consistent use with food. Extended-release formulations of metformin are available and associated with lower rates of GI intolerance compared to immediate-release tablets. Metformin is contraindicated in patients with severely reduced kidney function because reduced renal clearance can lead to lactic acidosis, a rare but serious metabolic complication. Dosing recommendations are adjusted based on eGFR. For patients beginning metformin or seeking to understand its role, learning about metformin for diabetes management provides a comprehensive clinical foundation. For patients who want to explore how metformin compares to other diabetes agents within the full prescribing landscape, the resources at diabetes medication category guides offer valuable comparative context.